TP53 mutation drives unique transcriptional and functional vulnerabilities independent of del(17p) in multiple myeloma.
A large study reveals that specific TP53 mutations—not a common chromosomal deletion—drive drug vulnerabilities in multiple myeloma, suggesting improved ways to select treatments.
Using genome-wide CRISPR-Cas9 screening and multi-omics profiling across 167 myeloma patient samples, this study establishes that TP53 mutations—not del(17p)—drive specific drug vulnerabilities including HDAC/HSP90 inhibitor sensitivity, with MDM2 independence. These findings challenge current standard practice of classifying high-risk MM by del(17p) alone and propose refined TP53 mutation-specific treatment strategies.
What the study was
- Study design
- Multi-omics ex vivo study; genome-wide CRISPR-Cas9 and RNAi screening; drug sensitivity profiling with genomics/transcriptomics/proteomics; 167 CD138+ bone marrow patient samples.
- Population
- 167 CD138+ bone marrow samples from multiple myeloma patients.
- Sample size
- 167
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- iScience
Why it surfaced
Multi-omics CRISPR evidence that TP53 mutation (not del(17p)) drives specific drug vulnerabilities in MM; challenges current classification; actionable for high-risk MM treatment decisions.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.